Atara plans to price IPO of 5 million shares between $14.00 and $16.00

Goldman Sachs, Citigroup are bookrunners; Jefferies is co-manager

By Devika Patel

Knoxville, Tenn., July 10 – Atara Biotherapeutics, Inc. will sell 5 million common shares in its initial public offering with a greenshoe for 750,000 additional shares, according to an S-1/A filed Thursday with the Securities and Exchange Commission. The deal was announced June 20.

The shares will be sold at a price expected to fall between $14.00 and $16.00 each.

Goldman Sachs & Co. and Citigroup Global Markets Inc. are the joint bookrunners. Jefferies LLC is the co-manager.

Proceeds will be used for clinical development and manufacturing, preclinical research, working capital and other general corporate purposes.

The biopharmaceutical company is based in Brisbane, Calif. The company intends to list its common stock on the Nasdaq Global Market under the symbol “ATRA.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.